EAN 2022 | sNfL predicts NEDA-status in a 6-year longitudinal cohort of MS patients

Serum neurofilament light chain (sNfL) is an emerging biomarker in multiple sclerosis (MS) and other neurological diseases. Stefan Bittner, MD, Johannes Gutenberg-University, Mainz, Germany, shares a study investigating the utility of sNfL for forecasting disease activity. A cohort of MS patients with no evidence of disease activity-3 (NEDA-3) – defined as no relapse, no disability worsening, and no MRI activity – was investigated. sNfL identified MS patients with severe focal axonal damage (NEDA-3 plus new T1-lesion) after six years. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.